342 related articles for article (PubMed ID: 15169800)
1. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management.
Cooperberg MR; Lubeck DP; Meng MV; Mehta SS; Carroll PR
J Clin Oncol; 2004 Jun; 22(11):2141-9. PubMed ID: 15169800
[TBL] [Abstract][Full Text] [Related]
2. Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry.
Borno HT; Cowan JE; Zhao S; Broering JM; Carroll PR; Ryan CJ
Urol Oncol; 2020 Oct; 38(10):793.e1-793.e11. PubMed ID: 32782182
[TBL] [Abstract][Full Text] [Related]
3. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
4. Prostate brachytherapy: a descriptive analysis from CaPSURE.
Lee WR; Sharkey J; Cowan JE; DuChane J; Carroll PR;
Brachytherapy; 2007; 6(2):123-8. PubMed ID: 17434105
[TBL] [Abstract][Full Text] [Related]
5. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.
Wilt TJ; MacDonald R; Rutks I; Shamliyan TA; Taylor BC; Kane RL
Ann Intern Med; 2008 Mar; 148(6):435-48. PubMed ID: 18252677
[TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation use with external beam radiation for prostate cancer: results from CaPSURE.
Park S; Meng MV; Elkin EP; Speight JL; DuChane J; Carroll PR
J Urol; 2005 Nov; 174(5):1802-7. PubMed ID: 16217291
[TBL] [Abstract][Full Text] [Related]
7. Contemporary trends in low risk prostate cancer: risk assessment and treatment.
Cooperberg MR; Broering JM; Kantoff PW; Carroll PR
J Urol; 2007 Sep; 178(3 Pt 2):S14-9. PubMed ID: 17644125
[TBL] [Abstract][Full Text] [Related]
8. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE.
Harlan SR; Cooperberg MR; Elkin E; Lubeck DP; Meng M; Mehta SS; Carroll PR
J Urol; 2003 Nov; 170(5):1804-7. PubMed ID: 14532780
[TBL] [Abstract][Full Text] [Related]
9. Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE).
Meng MV; Elkin EP; Latini DM; Duchane J; Carroll PR
J Urol; 2005 May; 173(5):1557-61. PubMed ID: 15821485
[TBL] [Abstract][Full Text] [Related]
10. Time trends and local variation in primary treatment of localized prostate cancer.
Cooperberg MR; Broering JM; Carroll PR
J Clin Oncol; 2010 Mar; 28(7):1117-23. PubMed ID: 20124165
[TBL] [Abstract][Full Text] [Related]
11. Trends of the primary therapy for patients with prostate cancer in Nara uro-oncological research group (NUORG): a comparison between the CaPSURE data and the NUORG data.
Tanaka N; Fujimoto K; Hirayama A; Yoneda T; Yoshida K; Hirao Y
Jpn J Clin Oncol; 2010 Jun; 40(6):588-92. PubMed ID: 20299498
[TBL] [Abstract][Full Text] [Related]
12. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
13. Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT.
Hamdy FC; Donovan JL; Lane JA; Mason M; Metcalfe C; Holding P; Wade J; Noble S; Garfield K; Young G; Davis M; Peters TJ; Turner EL; Martin RM; Oxley J; Robinson M; Staffurth J; Walsh E; Blazeby J; Bryant R; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Gnanapragasam V; Hughes O; Kockelbergh R; Kynaston H; Paul A; Paez E; Powell P; Prescott S; Rosario D; Rowe E; Neal D
Health Technol Assess; 2020 Aug; 24(37):1-176. PubMed ID: 32773013
[TBL] [Abstract][Full Text] [Related]
14. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry.
Cooperberg MR; Broering JM; Litwin MS; Lubeck DP; Mehta SS; Henning JM; Carroll PR;
J Urol; 2004 Apr; 171(4):1393-401. PubMed ID: 15017184
[TBL] [Abstract][Full Text] [Related]
15. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy.
Cooperberg MR; Hinotsu S; Namiki M; Ito K; Broering J; Carroll PR; Akaza H
J Clin Oncol; 2009 Sep; 27(26):4306-13. PubMed ID: 19667269
[TBL] [Abstract][Full Text] [Related]
16. Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer.
Muralidhar V; Mahal BA; Butler S; Lamba N; Yang DD; Leeman J; D'Amico AV; Nguyen PL; Trinh QD; Orio PF; King MT
J Urol; 2019 Nov; 202(5):973-978. PubMed ID: 31144590
[TBL] [Abstract][Full Text] [Related]
17. Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.
Ravi P; Karnes RJ; Rangel LJ; Pagliaro LC
J Urol; 2018 Nov; 200(5):1075-1081. PubMed ID: 29709664
[TBL] [Abstract][Full Text] [Related]
18. Relative influence of Gleason score and pretreatment PSA in predicting survival following brachytherapy for prostate cancer.
Beyer DC; Thomas T; Hilbe J; Swenson V
Brachytherapy; 2003; 2(2):77-84. PubMed ID: 15062144
[TBL] [Abstract][Full Text] [Related]
19. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.
Kishan AU; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Sandler KA; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Stephenson AJ; Klein EA; Song DY; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco S; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR
JAMA; 2018 Mar; 319(9):896-905. PubMed ID: 29509865
[TBL] [Abstract][Full Text] [Related]
20. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.
Nair B; Wilt T; MacDonald R; Rutks I
Cochrane Database Syst Rev; 2002; (1):CD003506. PubMed ID: 11869665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
